Abstract
Cancer being a multifactorial disease, its genesis and progression are enormously complicated. The classical chemotherapeutics along with recent targeted molecular therapy approach have not been effective in complete eradication of all tumor cells and is often been limited by drug resistance and side effects on normal tissues and cells. With the fast evolving field of genomics and molecular medicine translating into precision medicine, the importance of individualized therapeutic protocols has been realized. For transitioning from surgical treatments to radiotherapy to chemo and immunotherapies, in this fast advancing world, it will not be far away when the personalized medicine will be the choice of treatment for one and all. The major challenge in the anticancer drug development is multidrug resistance and relapse. In this chapter, we describe the promising anticancer targets in different phases of drug development in clinical trials along with new drug targets for personalized cancer treatment in near future.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Tobore TO (2019) On the need for the development of a cancer early detection, diagnostic, prognosis, and treatment response system. Future Sci OA 6(2):FSO439
Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7–30
Aggarwal V, Banday AZ, Jindal AK, Das J, Rawat A (2020) Recent advances in elucidating the genetics of common variable immunodeficiency. Genes Dis 7(1):26–37
Aggarwal V, Das A, Bal A, Srinivasan R, Das R, Prakash G et al (2019) MYD88, CARD11, and CD79B oncogenic mutations are rare events in the indian cohort of de novo nodal diffuse large B-cell lymphoma. Appl Immunohistochem Mol Morphol 27(4):311–318
Aggarwal V, Kashyap D, Sak K, Tuli HS, Jain A, Chaudhary A et al (2019) Molecular mechanisms of action of tocotrienols in cancer: recent trends and advancements. Int J Mol Sci 20(3):656
Aggarwal V, Priyanka K, Tuli HS (2020) Emergence of circulating MicroRNAs in breast cancer as diagnostic and therapeutic efficacy biomarkers. Mol Diagn Ther 24(2):153–173
Zhang H, Chen J (2018) Current status and future directions of cancer immunotherapy. J Cancer 9(10):1773–1781
Fodale V, Pierobon M, Liotta L, Petricoin E (2011) Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance? Cancer J 17(2):89–95
Fu B, Wang N, Tan HY, Li S, Cheung F, Feng Y (2018) Multi-component herbal products in the prevention and treatment of chemotherapy-associated toxicity and side effects: a review on experimental and clinical evidences. Front Pharmacol 9:1394
Bashraheel SS, Domling A, Goda SK (2020) Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine. Biomed Pharmacother 125:110009
Aggarwal V, Tuli HS, Kaur J, Aggarwal D, Parashar G, Chaturvedi Parashar N et al (2020) Garcinol exhibits anti-neoplastic effects by targeting diverse oncogenic factors in tumor cells. Biomedicine 8(5):103
Aggarwal V, Tuli HS, Tania M, Srivastava S, Ritzer EE, Pandey A et al (2020) Molecular mechanisms of action of epigallocatechin gallate in cancer: recent trends and advancement. Semin Cancer Biol 24:S1044-579X(20)30107-3
Aggarwal V, Tuli HS, Thakral F, Singhal P, Aggarwal D, Srivastava S et al (2020) Molecular mechanisms of action of hesperidin in cancer: recent trends and advancements. Exp Biol Med (Maywood) 245(5):486–497
Aggarwal V, Tuli HS, Varol A, Thakral F, Yerer MB, Sak K et al (2019) Role of reactive oxygen species in cancer progression: molecular mechanisms and recent advancements. Biomol Ther 9(11):735
Lopes A, Vandermeulen G, Preat V (2019) Cancer DNA vaccines: current preclinical and clinical developments and future perspectives. J Exp Clin Cancer Res 38(1):146
Guo C, Manjili MH, Subjeck JR, Sarkar D, Fisher PB, Wang XY (2013) Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res 119:421–475
Hollingsworth RE, Jansen K (2019) Turning the corner on therapeutic cancer vaccines. NPJ Vaccines 4:7
Exley C (2017) The safety of Cervarix? Lancet Infect Dis 17(1):19–20
Zhai L, Tumban E (2016) Gardasil-9: a global survey of projected efficacy. Antivir Res 130:101–109
Splawn LM, Bailey CA, Medina JP, Cho JC (2018) Heplisav-B vaccination for the prevention of hepatitis B virus infection in adults in the United States. Drugs Today (Barc) 54(7):399–405
Mougel A, Terme M, Tanchot C (2019) Therapeutic cancer vaccine and combinations with Antiangiogenic therapies and immune checkpoint blockade. Front Immunol 10:467
Redelman-Sidi G, Glickman MS, Bochner BH (2014) The mechanism of action of BCG therapy for bladder cancer--a current perspective. Nat Rev Urol 11(3):153–162
Handy CE, Antonarakis ES (2018) Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. Future Oncol 14(10):907–917
Gatti-Mays ME, Redman JM, Collins JM, Bilusic M (2017) Cancer vaccines: enhanced immunogenic modulation through therapeutic combinations. Hum Vaccin Immunother 13(11):2561–2574
di Pietro A, Tosti G, Ferrucci PF, Testori A (2008) Oncophage: step to the future for vaccine therapy in melanoma. Expert Opin Biol Ther 8(12):1973–1984
Ryman JT, Meibohm B (2017) Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol 6(9):576–588
Breedveld FC (2000) Therapeutic monoclonal antibodies. Lancet 355(9205):735–740
Geng X, Kong X, Hu H, Chen J, Yang F, Liang H et al (2015) Research and development of therapeutic mAbs: an analysis based on pipeline projects. Hum Vaccin Immunother 11(12):2769–2776
Weiner LM, Surana R, Wang S (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10(5):317–327
Kinder M, Greenplate AR, Strohl WR, Jordan RE, Brezski RJ (2015) An fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions. MAbs 7(3):494–504
Coulson A, Levy A, Gossell-Williams M (2014) Monoclonal antibodies in cancer therapy: mechanisms, successes and limitations. West Indian Med J 63(6):650–654
Longenecker G, Kulkarni AB (2009) Generation of gene knockout mice by ES cell microinjection. Curr Protoc Cell Biol. Chapter 19:Unit 19 4 4 1–36
Scott AM, Allison JP, Wolchok JD (2012) Monoclonal antibodies in cancer therapy. Cancer Immun 12:14
Sgro C (1995) Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review. Toxicology 105(1):23–29
Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J et al (2001) Initial sequencing and analysis of the human genome. Nature 409(6822):860–921
Liang F, Holt I, Pertea G, Karamycheva S, Salzberg SL, Quackenbush J (2000) Gene index analysis of the human genome estimates approximately 120,000 genes. Nat Genet 25(2):239–240
Matsubara K, Okubo K (1993) Identification of new genes by systematic analysis of cDNAs and database construction. Curr Opin Biotechnol 4(6):672–677
Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D et al (2009) Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 458(7235):223–227
Guttman M, Garber M, Levin JZ, Donaghey J, Robinson J, Adiconis X et al (2010) Ab initio reconstruction of cell type-specific transcriptomes in mouse reveals the conserved multi-exonic structure of lincRNAs. Nat Biotechnol 28(5):503–510
Marques AC, Ponting CP (2009) Catalogues of mammalian long noncoding RNAs: modest conservation and incompleteness. Genome Biol 10(11):R124
Wang WT, Han C, Sun YM, Chen TQ, Chen YQ (2019) Noncoding RNAs in cancer therapy resistance and targeted drug development. J Hematol Oncol 12(1):55
Esteller M (2011) Non-coding RNAs in human disease. Nat Rev Genet 12(12):861–874
Guttman M, Rinn JL (2012) Modular regulatory principles of large non-coding RNAs. Nature 482(7385):339–346
Matsui M, Corey DR (2017) Non-coding RNAs as drug targets. Nat Rev Drug Discov 16(3):167–179
Yoon S, Rossi JJ (2018) Therapeutic potential of small activating RNAs (saRNAs) in human cancers. Curr Pharm Biotechnol 19(8):604–610
Bainschab A, Quehenberger F, Greinix HT, Krause R, Wolfler A, Sill H et al (2016) Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: risk factors and efficacy of antibiotic prophylaxis. Leuk Res 42:47–51
Diesch J, Zwick A, Garz AK, Palau A, Buschbeck M, Gotze KS (2016) A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers. Clin Epigenetics 8:71
Corra F, Agnoletto C, Minotti L, Baldassari F, Volinia S (2018) The network of non-coding RNAs in cancer drug resistance. Front Oncol 8:327
Chi HC, Tsai CY, Tsai MM, Yeh CT, Lin KH (2017) Roles of long noncoding RNAs in recurrence and metastasis of radiotherapy-resistant cancer stem cells. Int J Mol Sci 18(9):1903
Mueller AK, Lindner K, Hummel R, Haier J, Watson DI, Hussey DJ (2016) MicroRNAs and their impact on radiotherapy for cancer. Radiat Res 185(6):668–677
El Fatimy R, Subramanian S, Uhlmann EJ, Krichevsky AM (2017) Genome editing reveals glioblastoma addiction to MicroRNA-10b. Mol Ther 25(2):368–378
Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, Hung G et al (2013) The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res 73(3):1180–1189
Chang RM, Xiao S, Lei X, Yang H, Fang F, Yang LY (2017) miRNA-487a promotes proliferation and metastasis in hepatocellular carcinoma. Clin Cancer Res 23(10):2593–2604
Iversen PL, Arora V, Acker AJ, Mason DH, Devi GR (2003) Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a phase I safety study in humans. Clin Cancer Res 9(7):2510–2519
Sekhon HS, London CA, Sekhon M, Iversen PL, Devi GR (2008) C-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model. Lung Cancer 60(3):347–354
Wang K, Kievit FM, Zhang M (2016) Nanoparticles for cancer gene therapy: recent advances, challenges, and strategies. Pharmacol Res 114:56–66
Zhou Z, Liu X, Zhu D, Wang Y, Zhang Z, Zhou X et al (2017) Nonviral cancer gene therapy: delivery cascade and vector nanoproperty integration. Adv Drug Deliv Rev 115:115–154
El-Aneed A (2004) An overview of current delivery systems in cancer gene therapy. J Control Release 94(1):1–14
Breyer B, Jiang W, Cheng H, Zhou L, Paul R, Feng T et al (2001) Adenoviral vector-mediated gene transfer for human gene therapy. Curr Gene Ther 1(2):149–162
Bertram JS (2000) The molecular biology of cancer. Mol Asp Med 21(6):167–223
Kirn D, Niculescu-Duvaz I, Hallden G, Springer CJ (2002) The emerging fields of suicide gene therapy and virotherapy. Trends Mol Med 8(4 Suppl):S68–S73
Mullen CA (1994) Metabolic suicide genes in gene therapy. Pharmacol Ther 63(2):199–207
Barajas M, Mazzolini G, Genove G, Bilbao R, Narvaiza I, Schmitz V et al (2001) Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology 33(1):52–61
Shi F, Rakhmilevich AL, Heise CP, Oshikawa K, Sondel PM, Yang NS et al (2002) Intratumoral injection of interleukin-12 plasmid DNA, either naked or in complex with cationic lipid, results in similar tumor regression in a murine model. Mol Cancer Ther 1(11):949–957
Hanke P, Serwe M, Dombrowski F, Sauerbruch T, Caselmann WH (2002) DNA vaccination with AFP-encoding plasmid DNA prevents growth of subcutaneous AFP-expressing tumors and does not interfere with liver regeneration in mice. Cancer Gene Ther 9(4):346–355
Conry RM, White SA, Fultz PN, Khazaeli M, Strong TV, Allen KO et al (1998) Polynucleotide immunization of nonhuman primates against carcinoembryonic antigen. Clin Cancer Res 4(11):2903–2912
Walther W, Stein U, Fichtner I, Voss C, Schmidt T, Schleef M et al (2002) Intratumoral low-volume jet-injection for efficient nonviral gene transfer. Mol Biotechnol 21(2):105–115
Cusack JC Jr, Tanabe KK (2002) Introduction to cancer gene therapy. Surg Oncol Clin N Am 11(3):497–519
Banas K, Rivera-Torres N, Bialk P, Yoo BC, Kmiec EB (2020) Kinetics of nuclear uptake and site-specific DNA cleavage during CRISPR-directed gene editing in solid tumor cells. Mol Cancer Res 18(6):891–902
Lee H, Yoon DE, Kim K (2020) Genome editing methods in animal models. Anim Cells Syst (Seoul) 24(1):8–16
Canalis E, Yu J, Schilling L, Yee SP, Zanotti S (2018) The lateral meningocele syndrome mutation causes marked osteopenia in mice. J Biol Chem 293(36):14165–14177
Duan X, Liu J, Zheng X, Wang Z, Zhang Y, Hao Y et al (2016) Deficiency of ATP6V1H causes bone loss by inhibiting bone resorption and bone formation through the TGF-beta1 pathway. Theranostics 6(12):2183–2195
Yao G, Feng H, Cai Y, Qi W, Kong K (2007) Characterization of vacuolar-ATPase and selective inhibition of vacuolar-H(+)-ATPase in osteoclasts. Biochem Biophys Res Commun 357(4):821–827
Zhang Y, Huang H, Zhao G, Yokoyama T, Vega H, Huang Y et al (2017) ATP6V1H deficiency impairs bone development through activation of MMP9 and MMP13. PLoS Genet 13(2):e1006481
Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR et al (2014) CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159(2):440–455
Kondo S, Kubota S, Shimo T, Nishida T, Yosimichi G, Eguchi T et al (2002) Connective tissue growth factor increased by hypoxia may initiate angiogenesis in collaboration with matrix metalloproteinases. Carcinogenesis 23(5):769–776
Okusha Y, Eguchi T, Tran MT, Sogawa C, Yoshida K, Itagaki M et al (2020) Extracellular vesicles enriched with moonlighting metalloproteinase are highly transmissive, pro-tumorigenic, and trans-activates cellular communication network factor (CCN2/CTGF): CRISPR against cancer. Cancers (Basel) 12(4):881
Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y et al (2008) Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 29(6):1235–1243
Morris SA, Farrell D, Grodzinski P (2014) Nanotechnologies in cancer treatment and diagnosis. J Natl Compr Cancer Netw 12(12):1727–1733
Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100(2):228–237
Gale RP (1985) Antineoplastic chemotherapy myelosuppression: mechanisms and new approaches. Exp Hematol 13(Suppl 16):3–7
Gharib MI, Burnett AK (2002) Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 4(3):235–242
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70
Baguley BC (2010) Multiple drug resistance mechanisms in cancer. Mol Biotechnol 46(3):308–316
Perez-Herrero E, Fernandez-Medarde A (2015) Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm 93:52–79
Gmeiner WH, Ghosh S (2015) Nanotechnology for cancer treatment. Nanotechnol Rev 3(2):111–122
Barenholz Y (2012) Doxil(R)--the first FDA-approved nano-drug: lessons learned. J Control Release 160(2):117–134
Clark AJ, Wiley DT, Zuckerman JE, Webster P, Chao J, Lin J et al (2016) CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing. Proc Natl Acad Sci U S A 113(14):3850–3854
Cui J, Richardson JJ, Bjornmalm M, Faria M, Caruso F (2016) Nanoengineered templated polymer particles: navigating the biological realm. Acc Chem Res 49(6):1139–1148
Fang RH, Jiang Y, Fang JC, Zhang L (2017) Cell membrane-derived nanomaterials for biomedical applications. Biomaterials 128:69–83
Richardson JJ, Bjornmalm M, Caruso F (2015) Multilayer assembly. Technology-driven layer-by-layer assembly of nanofilms. Science 348(6233):aaa2491
Yang X, Yang M, Pang B, Vara M, Xia Y (2015) Gold nanomaterials at work in biomedicine. Chem Rev 115(19):10410–10488
Shi J, Kantoff PW, Wooster R, Farokhzad OC (2017) Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer 17(1):20–37
Balasubramanian V, Liu Z, Hirvonen J, Santos HA (2018) Bridging the knowledge of different worlds to understand the big picture of cancer nanomedicines. Adv Healthc Mater 7(1). https://doi.org/10.1002/adhm.201700432
Stylianopoulos T, Jain RK (2015) Design considerations for nanotherapeutics in oncology. Nanomedicine 11(8):1893–1907
Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A et al (1998) Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 16(7):2445–2451
Nie S, Xing Y, Kim GJ, Simons JW (2007) Nanotechnology applications in cancer. Annu Rev Biomed Eng 9:257–288
Takeda M, Tada H, Higuchi H, Kobayashi Y, Kobayashi M, Sakurai Y et al (2008) In vivo single molecular imaging and sentinel node navigation by nanotechnology for molecular targeting drug-delivery systems and tailor-made medicine. Breast Cancer 15(2):145–152
Chaturvedi VK, Singh A, Singh VK, Singh MP (2019) Cancer nanotechnology: a new revolution for cancer diagnosis and therapy. Curr Drug Metab 20(6):416–429
Prabhu P, Patravale V (2012) The upcoming field of theranostic nanomedicine: an overview. J Biomed Nanotechnol 8(6):859–882
Ferrari M (2005) Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5(3):161–171
Singhal S, Nie S, Wang MD (2010) Nanotechnology applications in surgical oncology. Annu Rev Med 61:359–373
Bae KH, Chung HJ, Park TG (2011) Nanomaterials for cancer therapy and imaging. Mol Cells 31(4):295–302
Melancon MP, Stafford RJ, Li C (2012) Challenges to effective cancer nanotheranostics. J Control Release 164(2):177–182
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Aggarwal, V. et al. (2020). Designing Personalized and Innovative Novel Drug Therapies for Cancer Treatment. In: Tuli, H.S. (eds) Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models. Springer, Singapore. https://doi.org/10.1007/978-981-15-7586-0_11
Download citation
DOI: https://doi.org/10.1007/978-981-15-7586-0_11
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-7585-3
Online ISBN: 978-981-15-7586-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)